Abate As Industries Ltd has closed its trading window effective Wednesday, July 1, 2026, to comply with regulations ahead of its financial results for the quarter ended June 30, 2026. The window will remain shut until 48 hours after the announcement of the unaudited financial results for Q1FY26. This measure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Prevention of Insider Trading.

During this period, all directors, designated employees, insiders, and their immediate relatives are prohibited from entering into any transaction involving the securities of the company. The restriction ensures that no privileged information is utilized for trading purposes prior to the public disclosure of financial performance.

The trading window is scheduled to reopen 48 hours after the unaudited financial results for the quarter ending June 30, 2026, are declared to the stock exchanges. The specific date for the Board Meeting, where the results are likely to be considered, will be communicated by the company in a separate intimation.

Key Details

The closure is a standard procedural step implemented by listed companies to maintain market integrity and adhere to regulatory mandates during sensitive financial reporting periods.

[Abate AS Industries Limited](abate as industries) reported a consolidated net profit of ₹12.3 crore for the financial year ended March 31, 2026, a significant increase from ₹1.1 crore in the previous year. The company's consolidated revenue from operations for FY26 stood at ₹161.68 crore, representing growth of 67% compared to ₹96.6 crore in FY25. This performance was driven by the scaling of its healthcare platform and continued contribution from retail operations, alongside the generation of positive operating cash flow.

The Board of Directors, at its meeting held on May 29, 2026, approved the audited standalone and consolidated financial results for FY26. During an earnings conference call on June 3, 2026, management highlighted that FY26 was a validation year for the company's strategic transformation from a training and consulting structure to a diversified platform spanning retail, healthcare, and education. The company generated positive operating cash flow of approximately ₹6.1 crore during the year, compared to negative operating cash flow in FY25.

Financial Performance

On a standalone basis, the company recorded a net profit of ₹154.73 lakh for the year, with revenue from operations reaching ₹211.55 lakh. The standalone financial results for the quarter ended March 31, 2026, showed a net profit of ₹24.79 lakh on a total revenue of ₹35.55 lakh. The company reported a basic and diluted earnings per share (EPS) of ₹0.10 for the standalone entity for FY26, up from ₹0.07 in the previous year.

Operational Highlights and Outlook

The healthcare segment contributed approximately 22% to consolidated revenue, with management targeting a long-term mix of 70% to 80%. The company aims to build healthcare into the dominant contributor to profitability and long-term value creation. Management stated that it estimates around ₹50 crore of capital could be required to support future expansions, though alternatives are still being evaluated. The balance sheet strengthened during the year, with cash equivalents increasing to approximately ₹3.5 crore and net worth rising to approximately ₹199 crore.

The Statutory Auditors, M/s. Mahesh C. Solanki & Co., issued an unmodified opinion on the standalone and consolidated financial statements. The auditors noted that the consolidated figures for the corresponding quarter and year ended March 31, 2026, as reported in these financial results, have been approved by the Parent's Board of Directors but have not been subjected to review. The company also confirmed compliance with the new Labour Codes notified by the Government of India, stating that no material financial impact is expected.